Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Control Crohn Safe Trial
2017-004588-11Phase 4Active
- Sponsor
- Maastricht University
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of adalimumab in Crohn's disease (2 arms), sponsored by Maastricht University. Primary endpoint: Quartiles of clinical and biochemical disease remission at week 96. Started Sep 2019; status: active.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2017-004588-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004588-11.